| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
|
N Engl J Med
|
2010
|
8.10
|
|
2
|
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
|
Lancet Oncol
|
2011
|
3.58
|
|
3
|
The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.
|
Cancer
|
2002
|
2.07
|
|
4
|
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
|
Clin Cancer Res
|
2008
|
2.06
|
|
5
|
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
|
Clin Cancer Res
|
2009
|
2.04
|
|
6
|
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
|
Cancer Res
|
2007
|
1.96
|
|
7
|
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
|
Oncoimmunology
|
2012
|
1.78
|
|
8
|
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
|
Proc Natl Acad Sci U S A
|
2010
|
1.67
|
|
9
|
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
|
Clin Cancer Res
|
2008
|
1.54
|
|
10
|
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.
|
Proc Natl Acad Sci U S A
|
2007
|
1.53
|
|
11
|
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.
|
Cancer Immunol Immunother
|
2007
|
1.47
|
|
12
|
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
|
Clin Cancer Res
|
2005
|
1.30
|
|
13
|
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.
|
BMC Genomics
|
2007
|
1.24
|
|
14
|
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma.
|
Genes Chromosomes Cancer
|
2009
|
1.12
|
|
15
|
High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.
|
Clin Cancer Res
|
2007
|
1.12
|
|
16
|
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
|
Int J Cancer
|
2008
|
1.11
|
|
17
|
Genetic variation of antigen processing machinery components and association with cervical carcinoma.
|
Genes Chromosomes Cancer
|
2007
|
1.11
|
|
18
|
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
|
Int J Cancer
|
2006
|
1.05
|
|
19
|
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
|
J Transl Med
|
2013
|
1.02
|
|
20
|
An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
|
Cancer Res
|
2010
|
1.00
|
|
21
|
Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer.
|
Hum Pathol
|
2002
|
0.99
|
|
22
|
The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors.
|
Int J Cancer
|
2010
|
0.98
|
|
23
|
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.
|
Mod Pathol
|
2008
|
0.97
|
|
24
|
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
|
Cancer Immunol Immunother
|
2012
|
0.97
|
|
25
|
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
|
Int J Cancer
|
2006
|
0.94
|
|
26
|
Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer.
|
Cochrane Database Syst Rev
|
2014
|
0.93
|
|
27
|
Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer.
|
Int J Cancer
|
2002
|
0.93
|
|
28
|
Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
|
Clin Cancer Res
|
2008
|
0.92
|
|
29
|
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
|
Int J Cancer
|
2006
|
0.92
|
|
30
|
Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
|
Int J Cancer
|
2004
|
0.91
|
|
31
|
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
|
Cancer Immunol Immunother
|
2013
|
0.89
|
|
32
|
Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.
|
Int J Cancer
|
2005
|
0.88
|
|
33
|
Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines.
|
Carcinogenesis
|
2005
|
0.87
|
|
34
|
Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma.
|
Cancer
|
2007
|
0.86
|
|
35
|
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
|
Int J Cancer
|
2008
|
0.85
|
|
36
|
Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
|
Eur J Cancer
|
2013
|
0.84
|
|
37
|
Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.
|
J Infect Dis
|
2010
|
0.84
|
|
38
|
Anatomical basis for nerve-sparing radical hysterectomy: immunohistochemical study of the pelvic autonomic nerves.
|
Acta Obstet Gynecol Scand
|
2005
|
0.84
|
|
39
|
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
|
Genet Med
|
2007
|
0.82
|
|
40
|
Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.
|
BMC Cancer
|
2012
|
0.82
|
|
41
|
Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature.
|
Int J Gynecol Cancer
|
2014
|
0.82
|
|
42
|
Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study.
|
Int J Gynecol Cancer
|
2013
|
0.81
|
|
43
|
Sexual issues among cervical cancer survivors: how can we help women seek help?
|
Psychooncology
|
2014
|
0.81
|
|
44
|
A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass.
|
Proteome Sci
|
2012
|
0.81
|
|
45
|
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
|
Anticancer Agents Med Chem
|
2014
|
0.81
|
|
46
|
The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study.
|
Int J Gynecol Cancer
|
2013
|
0.80
|
|
47
|
Detection of cervical cancer recurrence during follow-up: a multivariable comparison of 9 frequently investigated serum biomarkers.
|
Gynecol Oncol
|
2013
|
0.80
|
|
48
|
Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance.
|
Support Care Cancer
|
2014
|
0.79
|
|
49
|
Nerve-sparing radical hysterectomy: local recurrence rate, feasibility, and safety in cervical cancer patients stage IA to IIA.
|
Int J Gynecol Cancer
|
2009
|
0.78
|
|
50
|
Endothelium specific matrilysin (MMP-7) expression in human cancers.
|
Matrix Biol
|
2007
|
0.78
|
|
51
|
Completing or Abandoning Radical Hysterectomy in Early-Stage Lymph Node-Positive Cervical Cancer: Impact on Disease-Free Survival and Treatment-Related Toxicity.
|
Int J Gynecol Cancer
|
2017
|
0.78
|
|
52
|
Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
|
Int J Cancer
|
2007
|
0.77
|
|
53
|
Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma.
|
Int J Gynecol Cancer
|
2016
|
0.76
|
|
54
|
Simultaneous mapping of human papillomavirus integration sites and molecular karyotyping in short-term cultures of cervical carcinomas by using 49-color combined binary ratio labeling fluorescence in situ hybridization.
|
Cancer Genet Cytogenet
|
2002
|
0.76
|
|
55
|
The negative predictive value of clinical examination with or without anesthesia versus magnetic resonance imaging for parametrial infiltration in cervical cancer stages IB1 to IIA.
|
Int J Gynecol Cancer
|
2013
|
0.76
|
|
56
|
Patients with penile cancer and the risk of (pre)malignant cervical lesions in female partners: a retrospective cohort analysis.
|
BJU Int
|
2013
|
0.76
|
|
57
|
Outcomes after total versus subtotal abdominal hysterectomy.
|
N Engl J Med
|
2003
|
0.75
|
|
58
|
Careful Dissection of the Distal Ureter Is Highly Important in Nerve-sparing Radical Pelvic Surgery: A 3D Reconstruction and Immunohistochemical Characterization of the Vesical Plexus.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
59
|
Long-term Pelvic Floor Function and Quality of Life After Radical Surgery for Cervical Cancer: A Multicenter Comparison Between Different Techniques for Radical Hysterectomy With Pelvic Lymphadenectomy.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
60
|
Pelvic lymphadenectomy improves survival in patients with cervical cancer with low-volume disease in the sentinel node: a retrospective multicenter cohort study.
|
Int J Gynecol Cancer
|
2014
|
0.75
|
|
61
|
Long-Term Morbidity and Quality of Life in Cervical Cancer Survivors: A Multicenter Comparison Between Surgery and Radiotherapy as Primary Treatment.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
62
|
Lack of TNFalpha mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation.
|
Mol Immunol
|
2007
|
0.75
|
|
63
|
A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy.
|
Int J Gynecol Cancer
|
2017
|
0.75
|